Last reviewed · How we verify
Select DMTs other than ozanimod — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Select DMTs other than ozanimod (Select DMTs other than ozanimod) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Select DMTs other than ozanimod TARGET | Select DMTs other than ozanimod | Bristol-Myers Squibb | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Select DMTs other than ozanimod CI watch — RSS
- Select DMTs other than ozanimod CI watch — Atom
- Select DMTs other than ozanimod CI watch — JSON
- Select DMTs other than ozanimod alone — RSS
Cite this brief
Drug Landscape (2026). Select DMTs other than ozanimod — Competitive Intelligence Brief. https://druglandscape.com/ci/select-dmts-other-than-ozanimod. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab